Please login to the form below

Not currently logged in
Email:
Password:

caplacizumab

This page shows the latest caplacizumab news and features for those working in and with pharma, biotech and healthcare.

Sanofi extends growth spurt thanks to Genzyme, Dupixent

Sanofi extends growth spurt thanks to Genzyme, Dupixent

from Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura (aTTP), which made its debut in Germany in October.

Latest news

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    bid for Ablynx in December, which the Ablynx Board rejected.  Novo Nordisk's particular interest was in lead asset caplacizumab, a Nanobody therapeutic which inhibits von Willebrand factor (vWF) for the ... Acquisition company. 7, 000. Ablynx/Sanofi.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics